This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Calgary directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Gaucher Disease Treated With Lentiviral-Mediated Gene Therapy: First Case.
Journal of inherited metabolic disease · 2026
Lentivirus-mediated gene therapy for Fabry disease
Nature Communications · 2021
Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low-dose total body irradiation, and rabbit antithymocyte globulin.
Clinical transplantation · 2020
Latest funding
- $606,576
A pilot project to demonstrate feasibility of a Canadian gene therapy clinical trials platform for rare genetic diseases: Gene Therapy for CD3delta Severe Combined Immune Deficiency.
CIHR · 2022 · Principal investigator
- $2,426,302
A pilot project to demonstrate feasibility of a Canadian gene therapy clinical trials platform for rare genetic diseases: Gene Therapy for CD3delta Severe Combined Immune Deficiency.
CIHR · 2022 · Principal investigator
4 publications.
Gaucher Disease Treated With Lentiviral-Mediated Gene Therapy: First Case.
Shafey M, Prokopishyn N, Khan A
Lentivirus-mediated gene therapy for Fabry disease
Khan A, Barber DL, Huang J, Rupar CA, Rip JW, Auray-Blais C, Boutin M, O’Hoski P, Gargulak K, McKillop WM
Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low-dose total body irradiation, and rabbit antithymocyte globulin.
Ousia S, Kalra A, Williamson TS, Prokopishyn N, Dharmani-Khan P, Khan FM, Jimenez-Zepeda V, Jamani K, Duggan PR, Daly A, Russell JA, Storek J
High serum level of antithymocyte globulin immediately before graft infusion is associated with a low likelihood of chronic, but not acute, graft-versus-host disease.
Chawla S, Dharmani-Khan P, Liu Y, Prokopishyn N, Amlish Munir M, Griffiths C, Khan FM, Stewart DA, Russell JA, Daly A, Storek J
A pilot project to demonstrate feasibility of a Canadian gene therapy clinical trials platform for rare genetic diseases: Gene Therapy for CD3delta Severe Combined Immune Deficiency.
Principal investigators: Wright, Nicola A; Cuvelier, Geoff; Grunebaum, Eyal; Guilcher, Greg; Kohn, Donald B; Lewis, Victor; Marwaha, Ashish K; Murguia-Favela, Luis E; Narendran, Aru; Prokopishyn, Nicole L; Romero Garcia, Zulema; Suresh, Sneha
Keywords: Adenine Base Editing; Gene Editing; Gene Therapy Clinical Trial; Inborn Errors Of Immunity; Rare Diseases; Severe Combined Immune Deficiency
A pilot project to demonstrate feasibility of a Canadian gene therapy clinical trials platform for rare genetic diseases: Gene Therapy for CD3delta Severe Combined Immune Deficiency.
Principal investigators: Wright, Nicola A; Cuvelier, Geoff; Grunebaum, Eyal; Guilcher, Greg; Kohn, Donald B; Lewis, Victor; Marwaha, Ashish K; Murguia-Favela, Luis E; Narendran, Aru; Prokopishyn, Nicole L; Romero Garcia, Zulema; Suresh, Sneha
Keywords: Adenine Base Editing; Gene Editing; Gene Therapy Clinical Trial; Inborn Errors Of Immunity; Rare Diseases; Severe Combined Immune Deficiency
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Ronan Foley and Armand Keating: 5 shared papers
- Ronan Foley and Christiane Auray-Blais: 4 shared papers
- Armand Keating and Christiane Auray-Blais: 4 shared papers
- Ronan Foley and Nicole Prokopishyn: 1 shared paper
- Armand Keating and Nicole Prokopishyn: 1 shared paper
- Nicole Prokopishyn and Mona Shafey: 1 shared paper
- Nicole Prokopishyn and Christiane Auray-Blais: 1 shared paper
- Pediatrics
- Mechanical Engineering
- Obstétrique et gynécologie
- Medicine
- Department of Oncology
Co-authors at University of Calgary, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.